益盛藥業(002566.SZ):人蔘、生脈注射液產品列入《新型冠狀病毒肺炎診療方案(試行第九版)》
格隆匯3月17日丨益盛藥業(002566.SZ)公佈,近日,國家衞生健康委員會和國家中醫藥管理局聯合發佈了《新型冠狀病毒肺炎診療方案(試行第九版)》。公司產品人蔘和生脈注射液列入臨牀治療期(確診病例)危重型推薦處方及推薦中成藥。
人蔘具有大補元氣,復脈固脱,補脾益肺,生津養血,安神益智。用於體虛欲脱,肢冷脈微,脾虛食少,肺虛喘咳,津傷口渴,內熱消渴,氣血虧虛,久病虛贏,驚悸失眠,陽痿宮冷。
生脈注射液為公司主導針劑產品,屬國家醫保目錄(甲類)品種,主要用於氣陰兩虧,脈虛欲脱的心悸、氣短,四肢厥冷、汗出、脈欲絕及心肌梗塞、心源性休克、感染性休克等具有上述證候者。
人蔘和生脈注射液連續被列為《新型冠狀病毒肺炎診療方案(試行第六/七/八版)》臨牀治療期(確診病例)危重型推薦用藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.